Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Share-based Compensation (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Share-based Compensation for 11 consecutive years, with $16.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 57.75% to $16.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $80.2 million, a 48.0% decrease, with the full-year FY2025 number at $80.2 million, down 48.0% from a year prior.
  • Share-based Compensation was $16.7 million for Q4 2025 at Intellia Therapeutics, down from $19.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $40.9 million in Q2 2024 to a low of $6.4 million in Q1 2021.
  • A 5-year average of $25.3 million and a median of $23.8 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 187.84% in 2022, then crashed 57.75% in 2025.
  • Intellia Therapeutics' Share-based Compensation stood at $14.6 million in 2021, then surged by 69.12% to $24.6 million in 2022, then soared by 42.3% to $35.0 million in 2023, then grew by 13.05% to $39.6 million in 2024, then plummeted by 57.75% to $16.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Share-based Compensation are $16.7 million (Q4 2025), $19.6 million (Q3 2025), and $22.0 million (Q2 2025).